3-(α-Acetonylbenzyl)-4-hydroxycoumarin sodium salt

• CAS: 129-06-6
• Catalog Number: ACM129066
• Category: Main Products
• Molecular Weight: 330.31
• Molecular Formula: C₁₉H₁₅O₄Na
• Synonyms: 3-(α-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT; Warfarinsodium; WARFARIN SODIUM, EP STANDARD; 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt; rac-sodium 2-oxo-3-[(1R)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-4-olate; warfarin sodium salt; Warfarin Sodium; waran; warcoumin; WARFARIN SODIUM SALT; 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM CLATHRATE; 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN; WARFARIN SODIUM, (CONTAINS ISOPROPYL ALCOHOL); athrombin; sodium 2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-olate; 3-(Alpha-Acetonylbenzyl)-4-Hydroxycoumarin Sodiuim Salt; Warfarin sodium; tintorane; marevan; Warfarin SodiuM (contains Isopropyl Alcohol); varfine; warfilone; zoocoumarin-sodium; panwarfin; 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT; coumadin; 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM; WARFARIN SODIUM (CONTAINS ISOPROPYL ALCOHOL); WARFARIN SODIUMLINE; 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol); 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
• IUPAC Name: sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate
• Canonical SMILES: CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+]
• InChI Key: KYITYFHKDODNCQ-UHFFFAOYSA-M
• Boiling Point: 515.2ºC at 760mmHg
• Flash Point: 188.8ºC
• Density: 1.307g/cm³
• Appearance: white or yellowish powder
• EC Number: 226-909-4
• Exact Mass: 330.08700
• Hazard Statements: T+:Verytoxic
• Packing Group: II
• Safety Description: S53-S36/37/39-S45
• Stability: Contact with strong oxidizers may cause fires and explosions.
• UN Number: 2811
• WGK Germany: 1

Case Study

Preparation of Warfarin Sodium Orally Disintegrating Tablets by 3D Printing

Tian, Pan, et al. Drug development and industrial pharmacy, 2018, 44(12), 1918-1923.

Warfarin sodium (3-(α-Acetonylbenzyl)-4-hydroxycoumarin sodium salt) is an important oral anticoagulant ingredient and is widely used to treat deep vein thrombosis, pulmonary embolism, atrial fibrillation and other diseases. In this work, 3D printing technology was used to achieve the preparation and production of individualized dose warfarin orally disintegrating tablets.
Preparation of warfarin sodium orally disintegrating tablets
· First, warfarin sodium, D-sucrose, pregelatinized starch, povidone K30, microcrystalline cellulose and silicon dioxide (ratio of 1:42.45:46.15:5.1:4.9:0.4) were mixed as printing powder for 3D printer. The powder was mixed by sieving and mixing, and the specific operation was to sieve 1 kg of powder with a 120-mesh screen for 3 times, and then put the powder into a plastic bag and mix for 5 minutes. The drug content (η) was 1%. The wetting agent was 38% (v/v) ethanol.
· Subsequently, the model is modeled using software such as computer-aided design (CAD) and preset parameters (cylindrical tablet radius (r) = 5 mm, tablet thickness (H) = 4.5, 3.0 or 1.5 mm). The powder is loaded into the powder box of the 3D printing rapid prototyping machine, and the wetting agent is loaded into the ink container. After printing is completed, wait for the tablet to dry and then take it out. The dosage of the tablet is controlled by the number of printed layers.

Effects of Warfarin Sodium Formulation and Manufacturing Variables on Its Performance

Rahman, Ziyaur, et al. International journal of pharmaceutics, 2015, 495(1), 19-30.

To understand the effects of manufacturing and formulation variables on warfarin sodium (WS, 3-(α-Acetonylbenzyl)-4-hydroxycoumarin sodium salt) product critical quality attributes (CQAs), eight tablet formulations were prepared by wet granulation (WG) or direct granulation compression (DC). The formulations contained either LM or LA as excipients, and the granulation liquid was either ethanol, isopropyl alcohol (IPA), or IPA-water mixture (50:50). The effects of different formulation and manufacturing variables on WS products are as follows:
· The drug conversion phase was primarily influenced by various formulation and manufacturing variables, which in turn CQAs such as hardness, disintegration time (DT), and dissolution of the product.
· Maintaining the WS crystalline phase in the product throughout its shelf-life and usage is crucial, as most quality deviations are a result of drug phase changes. DT and dissolution of direct compression formulations were faster than wet granulation formulations. Disintegration and dissolution rates of LM were faster than those of formulations containing LA. Stability results showed an increase in hardness and DT, and a decrease in dissolution rate and extent.
· To prevent the conversion from WS crystalline to amorphous phase, it is important to carefully select formulation components and processes, incorporate desiccants in the final product, or package the product in smaller dosage forms with minimal headspace to ensure quick usage after opening.

Custom Reviews

August 13, 2023

---

Applied to the field of pharmacy
The structure of 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt is the necessary structure of anticoagulant drugs, and it can be used to synthesize a variety of pharmaceutical materials through chemical modification.